| Date | Title | Description |
| 14.05.2018 | Augmenix, Inc. Announces Exciting Plans for the 2018 American Urological Association Meeting in San Francisco | BEDFORD, Mass.–(BUSINESS WIRE)–May 14, 2018–
Augmenix, Inc. is pleased to announce that they will be exhibiting at this year’s American Urological Association meeting in San Francisco, California. Located at Booth 6251 Hall D, the company w... |
| 28.12.2017 | Augmenix to Present at the 36th Annual J.P. Morgan Healthcare Conference | BEDFORD, Mass.–(BUSINESS WIRE)–December 28, 2017–
Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, tod... |
| 07.11.2017 | Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018 | First and only prostate cancer spacing device available for use in the U.S. clinically proven to preserve patient quality of life following radiation therapy
BEDFORD, Mass.–(BUSINESS WIRE)–November 7, 2017–
Augmenix, Inc., a medical technol... |
| 28.09.2017 | Augmenix Partners with Us TOO International to Stream Live Webcast and Q & A on Prostate Cancer Radiation Therapy | BEDFORD, Mass., & DES PLAINES, Ill.–(BUSINESS WIRE)–September 28, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that separate and protect organs at risk during ... |
| 26.09.2017 | Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy of SpaceOAR® Hydrogel in Patients Undergoing Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer | Application of SpaceOAR hydrogel significantly reduces rectal injury in a high-dose SBRT treated patient population
BEDFORD, Mass.–(BUSINESS WIRE)–September 26, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures ... |
| 20.09.2017 | Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology | BEDFORD, Mass.–(BUSINESS WIRE)–September 20, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, today annou... |
| 06.09.2017 | Augmenix Announces Positive Five-Year Long-Term Data Highlighting Significant Bowel and Sexual Quality of Life Benefits for Prostate Cancer Patients Treated with SpaceOAR® Hydrogel | Long-term results recently published in the International Journal of Radiation Oncology Biology and Physics confirm the continued benefit of rectal spacing previously reported three-year follow-up results1,2
BEDFORD, Mass.–(BUSINESS WIRE)–S... |
| 29.08.2017 | NICE Announces Interventional Procedure Guidance Supporting Use of Hydrogel Spacer in Treatment of Prostate Cancer in the UK | Decision based on data involving use of SpaceOAR® hydrogel to protect surrounding tissue during radiotherapy to treat prostate cancer.
BEDFORD, Mass.–(BUSINESS WIRE)–August 29, 2017–
Augmenix, Inc., a medical technology company that develop... |
| 23.08.2017 | Augmenix, Inc. Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR® Hydrogel | BEDFORD, Mass.–(BUSINESS WIRE)–August 23, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures and sells absorbable hydrogels that separate and protect organs at risk during radiotherapy, today announced that Palme... |
| 22.08.2017 | Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year | Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500
BEDFORD, Mass.–(BUSINESS WIRE)–August 22, 2017–
Augmenix, Inc., a medical technology company th... |
| 28.06.2017 | Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel | The Chaim Sheba Medical Center now offers the hydrogel spacer to reduce side-effects during prostate cancer radiation therapy
BEDFORD, Mass.–(BUSINESS WIRE)–June 28, 2017–
Augmenix, Inc., a medical technology company that develops, manufact... |
| 21.06.2017 | Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in New Zealand | Kathleen Kilgour Centre is the first cancer center in New Zealand to offer this innovative product to their community
TAURANGA, New Zealand–(BUSINESS WIRE)–June 22, 2017–
Augmenix, Inc., a medical technology company that develops, manufactu... |
| 30.05.2017 | SpaceOAR® System Receives Shonin Approval in Japan | Advanced hydrogel technology from Augmenix used during prostate cancer radiation therapy now available to cancer treatment centers in Japan.
BEDFORD, Mass.–(BUSINESS WIRE)–May 30, 2017–
Augmenix, Inc., a medical technology company that deve... |
| 02.05.2017 | Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada | Princess Margaret Cancer Centre to initiate a 20-patient pilot study to assess hydrogel spacer to reduce rectal toxicity during prostate cancer radiation therapy
TORONTO–(BUSINESS WIRE)–May 2, 2017–
Augmenix, Inc., a medical technology comp... |
| 24.02.2017 | Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment | Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potency
BEDFORD, Mass.–(BUSINESS WIRE)–February 24, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures, and sells pr... |
| 11.01.2017 | Augmenix Announces Positive Three-Year Long-Term Data Highlighting Benefits of SpaceOAR® Hydrogel Spacer for Patients with Prostate Cancer | Results published in the International Journal of Radiation Oncology Biology and Physics show on average no long-term declines in bowel and urinary quality of life for patients and 78% reduction in late rectal toxicity.
WALTHAM, Mass.–(BUSI... |
| 21.12.2016 | Augmenix To Present at the 35th Annual J.P. Morgan Healthcare Conference | WALTHAM, Mass.–(BUSINESS WIRE)–December 21, 2016–
Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, tod... |
| 17.11.2016 | Augmenix to Present at the Annual Piper Jaffray Healthcare Conference on Wednesday, November 30 | WALTHAM, Mass.–(BUSINESS WIRE)–November 17, 2016–
Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, tod... |
| 09.11.2016 | Augmenix Announces New Category 1 CPT® Code from the American Medical Association for Periprostatic Implantation of Biodegradable Material | The CPT Code establishes a standard reimbursement pathway for this new procedure which is performed with SpaceOAR® technology
WALTHAM, Mass.–(BUSINESS WIRE)–November 9, 2016–
Augmenix Inc., (http://www.spaceoar.com), a medical technology co... |
| 27.09.2016 | Augmenix Announces Positive SpaceOAR® Clinical Trial Results Demonstrating Superior Outcomes at 3-Years | Application of SpaceOAR hydrogel results in lower long-term rectal injury and higher patient quality of life scores
WALTHAM, Mass.–(BUSINESS WIRE)–September 27, 2016–
Today Augmenix, Inc. (http://www.spaceoar.com/), a medical technology com... |
| 18.08.2016 | Augmenix Ranked as One of America’s Fastest-Growing Private Companies | With a Three-Year Sales Growth of 643%, Augmenix is one of the Fastest Growing Private Companies as Recognized by Inc. Magazine
WALTHAM, Mass.–(BUSINESS WIRE)–August 18, 2016–
Inc. magazine has ranked Augmenix in the top 12% on its 35th ann... |
| 13.07.2016 | Augmenix Financing Will Enable Sales Growth | Funding Will Enable Accelerated Sales Growth and Development of Next Generation Products
WALTHAM, Mass.–(BUSINESS WIRE)–July 13, 2016–
Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outco... |
| 13.07.2016 | Augmenix Raises $6M Series E | WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced it secured $6 million in series E funding from exis... |
| 13.07.2016 | Augmenix Secures $6M in Series E Funding | Augmenix, Inc., a Waltham, Mass.-based developer of minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, secured $6m in series E funding.
Existing investors participated in the round.
The company intends t... |
| 09.01.2015 | DexCom elevates COO Sayer, Gregg to chairman | Personnel Moves | Dexcom Inc. (NSDQ:DXCM) said it promoted COO Kevin Sayer to president & CEO this week, elevating former chief executive Terry Gregg to executive chairman after 7 years in the corner office.
Sayer has been COO since January 2013 and pres... |
| 11.11.2014 | Augmenix wins CE Mark for TraceIT marking agents | Augmenix said it won CE Mark approval in Europe for its TraceIT fiducial marker and TraceIT gel system radiology marking agents.
The products are part of Augmenix’s TraceIT line of absorbable hydrogels used to mark tissues with CT, MR, cone... |
| 24.07.2014 | Augmenix Closes $10.8M Series D Funding | Augmenix Inc., a Waltham, MA-based developer of minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, closed a $10.8m Series D funding.
Backers included new investor Excelestar Ventures and existing investo... |
| 16.10.2009 | Augmenix Closes $6.1M Series B Financing Round | Augmenix, a Waltham, Mass.-based company focused on the development and commercialization of implantable biomaterial based solutions for improved radiotherapy safety and/or efficacy, has closed a $6.1m Series B financing round.
The round wa... |
